EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Michael Lauseker, Tomasz Sacha, Hana Klamova, Julia Yakoleva, Elza Lomaia, Dragana Milojkovic, Christian Fabisch, Franck E Nicolini, Ulla Olsson-Stromberg, Daniela Zackova, Krzysztof Lewandowski, Philipp Ernst und 29 weitere

Leukemia · 2026

DOI: 10.1038/s41375-026-02875-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2026. Verfasst von Michael Lauseker und 40 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München,…. Hauptthemen laut MEDLINE: Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The project was supported by funding of the European LeukemiaNet (ELN)., Grant FF04 of the IZKF Jena University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blast CrisisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansPrognosisFemaleMaleMiddle AgedAdultAgedRetrospective StudiesYoung AdultProspective StudiesAged, 80 and overRegistries

Autor:innen und Institutionen

  • Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München, Munich, Germany. lauseker@ibe.med.uni-muenchen.de.
  • Jagiellonian University Medical College, Department of Hematology, Krakow, Poland.
  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russia.
  • Research Department of Immuno-Oncology, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation.
  • Hammersmith Hospital, Imperial College NHS Trust, London, UK.

Förderung

  • The project was supported by funding of the European LeukemiaNet (ELN).
  • Grant FF04 of the IZKF Jena University Hospital

Zitieren

APA

Lauseker, M., Sacha, T., Klamova, H., Yakoleva, J., Lomaia, E., Milojkovic, D., Fabisch, C., Nicolini, F. E., Olsson-Stromberg, U., Zackova, D., Lewandowski, K., Ernst, P., Castagnetti, F., Hirschbühl, K., Zupan, I., Voskanyan, A., Gołos, A., Frietsch, J. J., Gil, J., …, & Brioli, A. (2026). Development of a prognostic scoring system for chronic myeloid leukemia in blast phase. Leukemia. https://doi.org/10.1038/s41375-026-02875-9

Vancouver

Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, et al. Development of a prognostic scoring system for chronic myeloid leukemia in blast phase. Leukemia. 2026. doi:10.1038/s41375-026-02875-9

BibTeX
@article{Lauseker2026,
  author = {Lauseker, Michael and Sacha, Tomasz and Klamova, Hana and Yakoleva, Julia and Lomaia, Elza and Milojkovic, Dragana and Fabisch, Christian and Nicolini, Franck E and Olsson-Stromberg, Ulla and Zackova, Daniela and Lewandowski, Krzysztof and Ernst, Philipp and Castagnetti, Fausto and Hirschbühl, Klaus and Zupan, Irena and Voskanyan, Astghik and Gołos, Aleksandra and Frietsch, Jochen J and Gil, Justyna and Faber, Edgar and Krause, Stefan W and Parry, Anne and Saussele, Susanne and Heibl, Sonja and Franke, Georg-Nikolaus and Casado, Luis Felipe and Paczkowska, Edyta and Hebart, Holger and Eder, Matthias and Anhut, Peter and Trautmann-Grill, Karolin and Szczepanek, Elzbieta and Südhoff, Thomas and Patkowska, Elzbieta and Kiani, Alexander and Ernst, Thomas and Apperley, Jane and Mayer, Jiri and Hochhaus, Andreas and Pfirrmann, Markus and Brioli, Annamaria},
  title = {Development of a prognostic scoring system for chronic myeloid leukemia in blast phase},
  journal = {Leukemia},
  year = {2026},
  doi = {10.1038/s41375-026-02875-9}
}
Kostenlos starten →